Agentix (Agentix) Debt-to-Equity : -0.04 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Agentix Debt-to-Equity?

Agentix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.10 Mil. Agentix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Agentix's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-2.85 Mil. Agentix's debt to equity for the quarter that ended in Dec. 2023 was -0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Agentix's Debt-to-Equity or its related term are showing as below:

AGTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.26 Med: -0.86 Max: -0.02
Current: -0.04

During the past 9 years, the highest Debt-to-Equity Ratio of Agentix was -0.02. The lowest was -1.26. And the median was -0.86.

AGTX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs AGTX: -0.04

Agentix Debt-to-Equity Historical Data

The historical data trend for Agentix's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agentix Debt-to-Equity Chart

Agentix Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

-0.87

-0.02

Agentix Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-0.02	-0.04	-0.02	-0.04

Competitive Comparison of Agentix's Debt-to-Equity

For the Biotechnology subindustry, Agentix's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agentix's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agentix's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Agentix's Debt-to-Equity falls into.

Agentix Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Agentix's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.05	+	0)	/	-2.249
	=	-0.02

Agentix's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.1	+	0)	/	-2.846
	=	-0.04

Agentix (OTCPK:AGTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Agentix Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Agentix's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Agentix (Agentix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agentix Corp (OTCPK:AGTX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

32932 Pacific Coast Highway, Suite 14-254, Dana Point, CA, USA, 92629

Website

https://www.agentixcorp.com

Agentix Corp is a biotechnology company. It is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space.

Executives

Thomas E Puzzo	10 percent owner	4216 NE 70TH STREET, SEATTLE WA 98115
Michael Winterhalter	director, 10 percent owner, officer: President, CEO, CFO, Treasurer	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Grays Peak Ventures Llc	10 percent owner	320 PARK AVE, NEW YORK NY 10022
Scott B Stevens	director, officer: President and Director	9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Robert K Whalen	director, officer: Secretary and Treasurer	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Scott Thomas	director	14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Robert Drust	director	14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Eric Krogius	director, 10 percent owner	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Bao Dong Han	10 percent owner	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629

Agentix (Agentix) Headlines

No Headlines